Last reviewed · How we verify
NCT06101043
PECS II Block and Single Port Robot-assisted Transaxillary Thyroidectomy
NA trial testing Pectoral nerve block in Thyroid Cancer in 76 participants. Status unknown.
28 September 2024
Quick facts
| Lead sponsor | Min Suk Chae |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 76 |
| Start date | 4 January 2024 |
| Primary completion | 28 September 2024 |
| Estimated completion | 30 September 2024 |
Drugs / interventions tested
- Pectoral nerve block — full drug profile →
Conditions studied
- Thyroid Cancer — all drugs for Thyroid Cancer →
Sponsor
Min Suk Chae
Who can join
Adults 19 to 60, any sex, with Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The da Vinci robotic system was developed to improve both operative maneuverability (through multi-articulated instruments) and the surgical view (via a three-dimensional camera). Although the system has many advantages, skin incision, wide flap dissection, and pneumatic/mechanical retraction remain essential, but cause postoperative pain and slower recovery. Previous studies found that pectoralis fascial blocks were easy to establish; local anesthetics are injected between two adjacent myofascial layers under ultrasound guidance, providing the surgeon with a clear image. Analgesic efficacy has been validated during robotic thyroidectomy in our institution. The pain outcomes were comparable between the groups, but there were fewer complications in the PECS II group. The investigators investigated whether this block can reduce postoperative pain during wide flap dissection for single-port robot-assisted transaxillary thyroidectomy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy of pectoral nerve II block for flap dissection-related pain following robot-assisted transaxillary thyroidectomy: a prospective, randomized controlled trial.
Chae MS, Kim K. · · 2026 · PMID 39988447 · DOI 10.4097/kja.24914
Verify or expand the search:
- PubMed search for NCT06101043
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thyroid Cancer
Currently open trials in the same condition.
- NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
- NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
- NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
- NCT07438847 — 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer · Phase 1 · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Other Min Suk Chae trials
Trials by the same sponsor.
- NCT06446583 — Preoperative Chewing Gum and Postoperative Nausea and Vomiting · NA · not yet recruiting
- NCT06312098 — Perioperative Factors and Living Donor Liver Transplantation · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06101043 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Min Suk Chae
- Last refreshed: 5 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06101043.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing